We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Test to Detect Protein Biomarkers Identified Using Breast Milk Could Enable Breast Cancer Screening

By LabMedica International staff writers
Posted on 05 Apr 2022

A simple blood test for women of all ages and risk levels could one day be possible thanks to a new set of protein biomarkers identified by researchers using breast milk. More...

The newly identified biomarkers are for a specific type of cancer called invasive ductal carcinoma (IDC), one of the most common types of breast cancers. However, the researchers at Clarkson University (Potsdam, NY, USA) who identified the biomarkers say that their approach could be used to identify biomarkers for other types of breast cancer. For the study, breast milk samples were obtained from three women diagnosed with breast cancer and three women without cancer. Using liquid chromatography with tandem mass spectrometry, the researchers compared the relative levels of certain proteins between the two groups to identify differences in the women with cancer. The analysis revealed 23 proteins that were dysregulated. All the proteins that showed differences were previously shown to play a role in cancer or tumor development.

Now that the researchers have identified a biomarker set, they plan to confirm it with a larger group of women. Then, they will test the protein biomarkers’ applicability in blood serum. If those tests are successful, a blood test could be developed to be used on women of any age to monitor protein changes for detection of breast cancer.

“Although mammograms are a useful tool for catching breast cancer early, they aren’t typically recommended for low-risk women under 40,” said Danielle Whitham, a doctoral candidate at Clarkson University. “Because the biomarkers we found in breast milk are also detectable in blood serum, screening could potentially be done in women of any age using blood or breast milk.”

“If our future studies are successful, it could change how women are monitored for breast cancer and aid in earlier diagnosis,” added Whitham. “This could even lead to a higher survival rate in women. We used breast milk because it contains proteins, epithelial cells and immune cells, all of which provide a great deal of information about what is happening in a woman’s body during a crucial time in breast development.”

Related Links:
Clarkson University 


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.